Analysts have been eager to weigh in on the Healthcare sector with new ratings on Fate Therapeutics (FATE) and Global Blood Therapeutics (GBT).
Fate Therapeutics (FATE)
In a report released today, Matthew Biegler from Oppenheimer maintained a Buy rating on Fate Therapeutics, with a price target of $135.00. The company’s shares closed last Wednesday at $95.27.
According to TipRanks.com, Biegler is a 5-star analyst with an average return of 60.6% and a 62.2% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Turning Point Therapeutics, Aptose Biosciences, and Homology Medicines.
Currently, the analyst consensus on Fate Therapeutics is a Strong Buy with an average price target of $104.25, which is a 7.7% upside from current levels. In a report issued on February 17, Piper Sandler also maintained a Buy rating on the stock with a $116.00 price target.
See today’s analyst top recommended stocks >>
Global Blood Therapeutics (GBT)
In a report released today, Raju Prasad from William Blair downgraded Global Blood Therapeutics to Hold. The company’s shares closed last Wednesday at $49.19.
According to TipRanks.com, Prasad is a 5-star analyst with an average return of 24.2% and a 61.9% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Crispr Therapeutics AG, and Rocket Pharmaceuticals.
Currently, the analyst consensus on Global Blood Therapeutics is a Moderate Buy with an average price target of $79.17, representing a 64.0% upside. In a report issued on February 16, Raymond James also maintained a Hold rating on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
